<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566643</url>
  </required_header>
  <id_info>
    <org_study_id>TCRD100-16</org_study_id>
    <secondary_id>IRB099-71</secondary_id>
    <nct_id>NCT01566643</nct_id>
  </id_info>
  <brief_title>Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections</brief_title>
  <official_title>Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective controlled randomized open-label clinical trial is designed to determine the
      optimal eradication rate of rabeprazole based sequential-concommitant hybrid therapies for
      adults infected with Helicobacter pylori in Eastern Taiwan. Enrolled patients will receive 3,
      5 or 7 days of pre-concommitant (sequential part) treatment with rabeprazole + amoxicillin,
      then 7 days of concommitant treatment with rabeprazole + amoxicillin + clarithromycin +
      metronidazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Antimicrobial resistance has decreased the worldwide eradication rates of common
      used triple therapy for Helicobacter pylori infection (less than 80%).

      Objective: To determine the optimal pre-concommitant treatment length for rabeprazole based
      sequential-concomitant hybrid therapies for adults infected with Helicobacter pylori in
      Eastern Taiwan.

      Design: Randomized, open-label, prospective controlled trial.

      Patients: 231 patients with dyspepsia or peptic ulcers and infected by Helicobacter pylori.

      Measurements: 13C-urea breath test, upper endoscopy, histologic evaluation, rapid urease
      test, bacterial culture, assessment of antibiotic resistance and CYP2C19 genotype of host.

      Intervention: 231 patients with Helicobacter pylori infection are recruited and randomly
      assigned to receive one of the following therapeutic schemes: group 1, 14-days hybrid
      therapy: rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg
      bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days;
      group 2, 12-days hybrid therapy: rabeprazole 20mg bid + amoxicillin 1g bid treated for 5
      days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid +
      metronidazole 0.5g bid for other 7 days; group 3, 10-days hybrid therapy: rabeprazole 20mg
      bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid +
      clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days. Repeat upper endoscopy for
      histologic evaluation, rapid urease test or 13C-urea breath test after 4 week of treatment to
      assess the treatment result. The influence on the hybrid therapies of antibiotic resistance
      of Helicobacter pylori and CYP2C19 genotype of host were determined.

      Expected results: The rabeprazole based sequential-concomitant therapies for eradication of
      Helicobacter pylori is very effective, and the outcome is not affected by antibiotic
      resistance of Helicobacter pylori and CYP2C19 genotype of host.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate</measure>
    <time_frame>4 weeks after complete use of drug for treatment</time_frame>
    <description>A negative post-treatment 13C-urea breath test result at more than 4 weeks after complete use of drug for treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Hybrid-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA3-RACM7: rabeprazole + amoxicillin x 3 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hybrid-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA5-RACM7: rabeprazole + amoxicillin x 5 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hybrid-14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA7-RACM7: rabeprazole + amoxicillin x 7 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RA5-RACM7</intervention_name>
    <description>rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days</description>
    <arm_group_label>Hybrid-12</arm_group_label>
    <other_name>Pariet x 12 days.</other_name>
    <other_name>Hiconcil x 12 days.</other_name>
    <other_name>Klarid x 7 days.</other_name>
    <other_name>Flagyl x 7 days.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RA3-RACM7</intervention_name>
    <description>rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days</description>
    <arm_group_label>Hybrid-10</arm_group_label>
    <other_name>Pariet x 10 days.</other_name>
    <other_name>Hiconcil x 10 days.</other_name>
    <other_name>Klarid x 7 days.</other_name>
    <other_name>Flagyl x 7 days.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RA7-RACM7</intervention_name>
    <description>rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days</description>
    <arm_group_label>Hybrid-14</arm_group_label>
    <other_name>Pariet x 14 days.</other_name>
    <other_name>Hiconcil x 14 days.</other_name>
    <other_name>Klarid x 7 days.</other_name>
    <other_name>Flagyl x 7 days.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient proved with infection of H. pylori in gastric mucosa (at least two of four
             tests positive)

        Exclusion Criteria:

          -  woman in breast feeding or pregnancy.

          -  allergy to drugs used in study.

          -  previously treated for H. pylori.

          -  intolerance to fructose, lactose.

          -  patients with hematologic, brain or spinal disorders

          -  patients under 20 years old

          -  patients under aspirin or clopidogrel

          -  patients with history of gastric cancer or gastric resection operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Cheh CHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Cheh CHEN, MD</last_name>
    <phone>+886-910-521003</phone>
    <email>MingCheh_chen@tzuchi.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>97002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Cheh CHEN, MD</last_name>
      <phone>+886-910-521003</phone>
      <email>MingCheh_chen@tzuchi.com.tw</email>
    </contact>
    <investigator>
      <last_name>Ming-Cheh CHEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Tan HU, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Yi RAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>April 4, 2012</last_update_submitted>
  <last_update_submitted_qc>April 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Buddhist Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Ming-Cheh Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>antibiotic resistance</keyword>
  <keyword>sequential-concomitant hybrid therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

